Chemotherapy-induced anemia in adults: incidence and treatment - PubMed (original) (raw)
Review
. 1999 Oct 6;91(19):1616-34.
doi: 10.1093/jnci/91.19.1616.
Affiliations
- PMID: 10511589
- DOI: 10.1093/jnci/91.19.1616
Review
Chemotherapy-induced anemia in adults: incidence and treatment
J E Groopman et al. J Natl Cancer Inst. 1999.
Erratum in
- J Natl Cancer Inst 2000 Mar 15;92(6):497
Abstract
Anemia is a common complication of myelosuppressive chemotherapy that results in a decreased functional capacity and quality of life (QOL) for cancer patients. Severe anemia is treated with red blood cell transfusions, but mild-to-moderate anemia in patients receiving chemotherapy has traditionally been managed conservatively on the basis of the perception that it was clinically unimportant. This practice has been reflected in the relative inattention to standardized and complete reporting of all degrees of chemotherapy-induced anemia. We undertook a comprehensive review of published chemotherapy trials of the most common single agents and combination chemotherapy regimens, including the new generation of chemotherapeutic agents, used in the treatment of the major nonmyeloid malignancies in adults to characterize and to document the incidence and severity of chemotherapy-induced anemia. Despite identified limitations in the grading and reporting of treatment-related anemia, the results confirm a relatively high incidence of mild-to-moderate anemia. Recent advances in assessing the relationships of anemia, fatigue, and QOL in cancer patients are providing new insights into these closely related factors. Clinical data are emerging that suggest that mild-to-moderate chemotherapy-induced anemia results in a perceptible reduction in a patient's energy level and QOL. Future research may lead to new classifications of chemotherapy-induced anemia that can guide therapeutic interventions on the basis of outcomes and hemoglobin levels. Perceptions by oncologists and patients that lesser degrees of anemia must be endured without treatment may be overcome as greater emphasis is placed on the QOL of the oncology patient and as research provides further insights into the relationships between hemoglobin levels, patient well-being, and symptoms.
Similar articles
- [Anemia induced by solid tumor chemotherapy].
Stasi R, Abriani L, Beccaglia P, Terzoli E, Amadori S. Stasi R, et al. Recenti Prog Med. 2002 Nov;93(11):585-601. Recenti Prog Med. 2002. PMID: 12489477 Review. Italian. - Anemia in oncology practice: relation to diseases and their therapies.
Tas F, Eralp Y, Basaran M, Sakar B, Alici S, Argon A, Bulutlar G, Camlica H, Aydiner A, Topuz E. Tas F, et al. Am J Clin Oncol. 2002 Aug;25(4):371-9. doi: 10.1097/00000421-200208000-00011. Am J Clin Oncol. 2002. PMID: 12151968 - Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N, Sriuranpong V, Suwanrusme H. Voravud N, et al. J Med Assoc Thai. 2007 Jun;90(6):1082-8. J Med Assoc Thai. 2007. PMID: 17624200 Clinical Trial. - Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.
Quirt I, Robeson C, Lau CY, Kovacs M, Burdette-Radoux S, Dolan S, Tang SC, McKenzie M, Couture F; Canadian Eprex Oncology Study Group. Quirt I, et al. J Clin Oncol. 2001 Nov 1;19(21):4126-34. doi: 10.1200/JCO.2001.19.21.4126. J Clin Oncol. 2001. PMID: 11689580 Clinical Trial. - Recombinant human erythropoietin in cancer-related anemia. Review of clinical evidence.
Crawford J. Crawford J. Oncology (Williston Park). 2002 Sep;16(9 Suppl 10):41-53. Oncology (Williston Park). 2002. PMID: 12380954 Review.
Cited by
- Evaluating the impact of loperamide on irinotecan-induced adverse events: a disproportionality analysis of data from the World Health Organization pharmacovigilance database (VigiBase).
Akagi T, Hamano H, Miyamoto H, Takeda T, Zamami Y, Ohyama K. Akagi T, et al. Eur J Clin Pharmacol. 2025 Jan;81(1):129-137. doi: 10.1007/s00228-024-03767-6. Epub 2024 Oct 23. Eur J Clin Pharmacol. 2025. PMID: 39443366 - Comparison of red blood cell hemolysis using plasma and serum separation tubes for outpatient specimens.
Ko DH, Won D, Jeong TD, Lee W, Chun S, Min WK. Ko DH, et al. Ann Lab Med. 2015 Mar;35(2):194-7. doi: 10.3343/alm.2015.35.2.194. Epub 2015 Feb 12. Ann Lab Med. 2015. PMID: 25729720 Free PMC article. - Safety of intravenous iron use in chronic kidney disease.
Kalra PA, Bhandari S. Kalra PA, et al. Curr Opin Nephrol Hypertens. 2016 Nov;25(6):529-535. doi: 10.1097/MNH.0000000000000263. Curr Opin Nephrol Hypertens. 2016. PMID: 27557350 Free PMC article. Review. - Association between serum levels of C-reactive protein and response to treatment of chemotherapy-induced anemia in patients with solid tumors: a multicenter, prospective, observational study.
Esquerdo Galiana G, Cervera JM, Barrajón E, Juárez A, Llorca C, Díaz N, López A, Peiró R. Esquerdo Galiana G, et al. Med Oncol. 2013 Mar;30(1):417. doi: 10.1007/s12032-012-0417-3. Epub 2013 Feb 1. Med Oncol. 2013. PMID: 23371041 - In Vivo Chemoprotective Activity of Bovine Dialyzable Leukocyte Extract in Mouse Bone Marrow Cells against Damage Induced by 5-Fluorouracil.
Coronado-Cerda EE, Franco-Molina MA, Mendoza-Gamboa E, Prado-García H, Rivera-Morales LG, Zapata-Benavides P, Rodríguez-Salazar Mdel C, Caballero-Hernandez D, Tamez-Guerra RS, Rodríguez-Padilla C. Coronado-Cerda EE, et al. J Immunol Res. 2016;2016:6942321. doi: 10.1155/2016/6942321. Epub 2016 Apr 17. J Immunol Res. 2016. PMID: 27191003 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical